Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients
Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients
复制标题
DOI：
10.1007/s12282-012-0406-6
复制
发表时间：
2014-07-01
期刊：
影响因子：
4
通讯作者：
Saito, Mitsue
中科院分区：
文献类型：
--
作者：
Karasawa, Kumiko;Kunogi, Hiroaki;Saito, Mitsue
目的：评价低分割全乳房放疗(HF-WBI)与常规分割(CF)全乳放疗的疗效和安全性。在3.2周内，HF-WBI以43.2Gy16次/次的剂量照射全乳房，对于手术切缘阳性或<lt；5 mm者，在肿瘤床上增加8.1Gy3次/3次，持续3天。从2006年4月1日到2010年12月31日，根据切缘状况，CF-WBI在5周内对全乳腺进行了50Gy25次的照射，并在1.4周内8次增加16Gy8次，在3天内增加到6Gy3次。在同一时期，381名患者和393个符合研究标准的乳房选择了CF-WBI，因此参与比较的患者总数为1,098人。HF-WBI组有24名患者(3%)出现2级急性皮肤反应，CF-WBI组有53名患者(14%)(P<；0.001)。中位随访期27个月。两组均观察到2例乳房内肿瘤复发。1例HF-WBI患者和2例CF-WBI患者出现区域淋巴结复发。在急性皮肤反应方面，HF-WBI优于CF-WBI，且具有相同的短期疗效。
To evaluate the efficacy and safety of hypofractionated whole-breast irradiation (HF-WBI) compared with conventionally fractionated (CF) WBI.Patients with early breast cancer (stages 0-II and < 3 positive lymph nodes) who had undergone breast-conserving surgery were eligible for the HF-WBI study. HF-WBI was administered at 43.2 Gy in 16 fractions over 3.2 weeks to the whole breast with an additional tumor-bed boost of 8.1 Gy in 3 fractions over 3 days for positive surgical margins or those < 5 mm. CF-WBI was administered at 50 Gy in 25 fractions over 5 weeks to the whole breast with an additional tumor-bed boost of 16 Gy in 8 fractions over 1.4 weeks to 6 Gy in 3 fractions over 3 days, depending on margin status.From April 1, 2006, to December 31, 2010, 717 patients were registered and 734 breasts were treated by HF-WBI. In the same period, 381 patients and 393 breasts who matched the study criteria chose CF-WBI, so the total number of patients in this comparison was 1,098. Grade 2 acute skin reactions were observed for 24 patients (3 %) in the HF-WBI group and 53 patients (14 %) in the CF-WBI (p < 0.001) group. The median follow-up period was 27 months. Two cases of intrabreast tumor recurrence were observed in each treatment group. Regional lymph node recurrence was observed in 1 HF-WBI patient and 2 CF-WBI patients.HF-WBI is superior to CF-WBI in terms of acute skin reaction and has the same short-term efficacy.